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Abstract
Background: While the few studies that have looked at the association between stunting and aflatoxin exposure
have found surprisingly large effects, the results remain inconclusive due to a lack of randomized controlled studies.
This protocol describes a non-blinded, cluster-randomized controlled trial with the specific objective of testing the
impact of reduced aflatoxin exposure on (individual) child linear growth.
Methods/Design: Participants were recruited from among households containing women in the last 5 months of
pregnancy in 28 maize-growing villages within Meru and Tharaka-Nithi Counties in Kenya. Households in villages
assigned to the intervention group are offered rapid testing of their stored maize for the presence of aflatoxin each
month; any maize found to contain more than 10 ppb aflatoxin is replaced with an equal amount of maize that
contains less than this concentration of the toxin. They are also offered the opportunity to buy maize that has been
tested and found to contain less than 10 ppb aflatoxin at local shops. Clusters (villages) were allocated to the
intervention group (28 villages containing 687 participating households) or control group (28 villages containing
536 participating households) using a random number generator. The trial, which is funded by United Kingdom
(UK) aid from the UK government, the Global Food Security Portal, and the Ministry for Foreign Affairs of Finland, is
currently ongoing.
Discussion: This study is the first randomized controlled trial (RCT) to test for a causal impact of aflatoxin exposure
on child growth. Whether or not this relationship is found, its results will have implications for the prioritization of
aflatoxin control efforts by governments in affected regions, as well as international donors.
Trial registration: American Economic Association RCT Registry # 0000105. Initial registration date: 6 November
2013, last updated 30 December 2014.
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Background
This protocol for the Mitigating Aflatoxin exposure to
Improve Child growth in Eastern Kenya (MAICE) study,
current as of 30 June 2015, is based on the SPIRIT (Stand-
ard Protocol Items: Recommendations for Interventional
Trials) reporting guidelines as detailed by Chan et al. [1].
A completed SPIRIT Checklist for the study is included as
Additional file 1. Aflatoxin is a naturally occurring toxic
by-product, named after a genus of fungus that produces
it (Aspergillus flavus and Aspergillus parasiticus). A. flavus
colonizes food crops including maize; A. parasiticus is a
concern in groundnuts as well as tree nuts (cashews and
pistachios) and a range of other produce1. Adverse im-
pacts of aflatoxin on human and livestock health are well-
established. For example, acute exposure in humans can
lead to liver disease, liver failure and death from aflatoxi-
cosis [2]. Aflatoxin has been classified by the International
Agency for Research on Cancer (IARC) as a Type 1 hu-
man carcinogen that causes hepatocellular carcinoma
(liver cancer) [3]. Additionally, chronic exposure to afla-
toxin among livestock reduces productivity and growth
rates [4].* Correspondence: v.hoffmann@cgiar.org
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The impact of chronic aflatoxin exposure on child
growth is not well-understood. In Ghana, women exhi-
biting high serum aflatoxin levels – a marker of having
been exposed over the previous 2 to 3 months – at de-
livery were more likely to have a low-birth weight baby;
no association was found with having a baby small for
gestational age or with preterm birth [5]. The analysis
controlled for socio-economic status (SES), but no de-
tails were provided on how this was done, making it
difficult to evaluate whether confounding was adequately
controlled for. A study in the Gambia showed that ex-
posure occurred before the linear growth retardation:
serum aflatoxin levels in pregnant women and in infants
at 16 weeks of age were strong predictors of linear growth
during the first year of life. Cord blood levels were not as-
sociated with birth weight or length [6]. The Gambia
study did not control for SES. A study in Benin and Togo
found that the serum aflatoxin level was 30–40 % higher
in stunted children 1 to 5 years of age than in non-stunted
children, after controlling for confounders including SES,
child age, and sex. Details on the measure of SES were not
provided by the authors [7]. Finally, the same authors
studied the linear growth of 200 Togolese children 16 to
37 months of age over an 8-month period. Children in the
highest serum aflatoxin albumin quartile grew 1.7 cm less
than children in the lowest quartile, after controlling for
age, sex, baseline length, and SES. As in the previous
study, the authors did not provide details on the SES
measure used [8].
Although these findings are generally consistent, none
of the studies used a controlled intervention method-
ology. As a consequence, it is not clear to what extent
the association between aflatoxin and child linear growth
was confounded by factors such as household SES, child
morbidity and dietary intake. For example, it may be the
case that poor households are less able to afford proper
post-harvest technologies to ensure that maize is fully
dried and properly stored; this would potentially lead to
poorer households consuming own-produced maize with
higher levels of aflatoxin contamination. Poorer house-
holds may also consume more aflatoxin as a result of
purchasing lower-quality maize. Poorer households also
have lower dietary intake and diversity, poorer sanita-
tion, and higher morbidity, which may manifest in
stunted children, thereby inducing a spurious correlation
between aflatoxin and child linear growth.
The specific objective of this study is to determine
whether consumption of aflatoxin has a direct causal im-
pact on child linear growth during the period from be-
fore birth to age 24 months. The hypothesized pathway
is a biological one: human and animal studies indicate
that aflatoxin causes immunosuppression (which in turn
can lead to repeated infections and, consequently, growth
retardation in young children), impairs protein synthesis,
and causes changes in the hepatic metabolism of micronu-
trients [4]. It has also been suggested that aflatoxin, to-
gether with fumonisin and deoxynivalenol (two other
mycotoxins commonly found in maize and groundnuts),
mediate intestinal damage similar to environmental enter-
opathy [9]. This condition is known to lead to chronic
systemic immune activation and malabsorption of nutri-
ents, which in turn may lead to growth retardation.
Testing the hypothesis that aflatoxin exposure impairs
child linear growth requires random assignment to re-
duced consumption of aflatoxin, keeping constant income,
food availability, and other factors that affect child linear
growth. A cluster-randomized design is necessary due to
the risk that under an individual-level randomization,
households assigned to the control group could potentially
access tested, aflatoxin-safe maize, provided to those in
the control group through the study. Despite the observed
association between aflatoxin exposure and adverse health
outcomes, enforcement of regulations to limit exposure is
weak in many less developed countries. An intervention
to systematically remove contaminated food from people’s
diets as implemented for this study is not currently feas-
ible outside of a research context due to logistical com-
plexity and cost. Comparison of the intervention against
status quo aflatoxin exposure is, therefore, justified.
Methods
Trial design
The study is based on a parallel-group design, with a
50:50 allocation of villages to the intervention and control
groups by simple random assignment using a computer-
generated sequence, implemented by the investigators.
Villages (the unit of randomization) are defined according
to their formal administrative boundaries.
Study site and selection of clusters
The study site is rural Meru and Tharaka-Nithi Counties
in Kenya, a known global hotspot for aflatoxin exposure
through maize. Outbreaks of acute aflatoxicosis were re-
ported in this region in 1981, 2004, 2005, and 2006, with
widespread contamination of maize reported in 2010
[10–15]. Villages in these two counties, which were
identified by a local agricultural expert as growing maize
as the predominant crop, were eligible for inclusion in
the study. Selection of these villages proceeded as follows:
one village was randomly selected using Stata’s random
number generator (StataCorp, College Station, TX, USA)
for inclusion in the study. A second village was then ran-
domly selected. Using the latitude and longitude of the vil-
lages, the second village was excluded from the study if it
was within 4 km from the original village, otherwise it was
retained in the study. This process continued, randomly
selecting villages and retaining them only if they were not
within 4 km of any other retained village, until 56 villages
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were selected for inclusion in the study. Due to the poten-
tial negative impact on maize farmers’ livelihoods of
making aflatoxin exposure levels in certain villages public,
the list of study villages is not publicly available.
Sample size
To determine sample size, the minimum detectable ef-
fect (MDE) for exposure to treatment for the full 24-
month period was set to 0.3 length-for-age Z-score
(LAZ), based on the magnitude of effect sizes that have
been obtained with known effective nutrition interven-
tions [16]. This was then adjusted for partial exposure to
the intervention of participants recruited in the first year
of the study (prior to introduction of the stockist com-
ponent) to give an MDE of 0.281.
Sample size calculations were performed to achieve an
alpha of 0.05 and power of 80 % to detect a difference of
means in LAZ between children in intervention and
control villages using a 1-sided test. Based on anthropo-
metric data collected in similar conditions, the standard
deviation of the LAZ of children was assumed to be
1.28. Assuming an intra-cluster correlation for LAZ of
0.05, attrition of 9 %, and that 15 % of variation in the
outcome would be explained by baseline variables, the
estimated total number of participants required to
achieve the study objectives was 924 across 56 villages
Eligibility and recruitment of participants
Enrollment of participants within these villages was con-
ducted by the African Population and Health Research
Center in 2013 and by Innovations for Poverty Action in
2014. Within each of the study villages, enrollment into
the study was conducted in 6 waves, each 4 months apart.
In each wave, women in the fifth to final month of preg-
nancy (by the woman’s estimate) were recruited to partici-
pate in the study. Scouts employed by the data collection
firm identified pregnant women in the study area before
the survey team arrived. This was done 6 times over the
course of recruitment, at 4-monthly intervals. Informed
consent was obtained from all participants as follows. The
consent form, included as Additional file 2, was read to
each potential participant by an enumerator at the initial
visit. The participant was then asked to sign the document
if he or she agreed to participate. All pregnant women
who gave informed consent in this way were enrolled in
the study. The number of recruitment waves required to
attain an adequate sample size was calculated using birth
rates from 2008 to 2009 Kenya Demographic and Health
Survey and populations of the study villages from the
2009 Kenya Census.
Intervention
The intervention consists of two components: swap and
stock. In the swapping component, households are visited
monthly by trained staff of Caritas Meru, a non-
governmental organization that works with farmers in
the study area, and offered rapid aflatoxin testing of
any stored maize that the household plans to consume
over the next 2 months. If the household agrees, a com-
posite sample of at least 150 grams of flour or 300
grams of whole kernels is taken from multiple regions
of the container in which the identified maize is stored,
and ground using a manual grinder, so that at least
70 % of the sample passes through a 20-mesh sieve, in
accordance with US Grain Inspection, Packers and
Stockyards Administration (GIPSA) aflatoxin testing
protocols. A rapid aflatoxin test is then conducted using a
10-gram sub-sample of the homogenized composite sam-
ple using the GIPSA-verified Romer (Romer Labs®, Inc.,
USA) AgraStrip rapid test with a 10 parts per billion (ppb)
detection threshold, according to manufacturer instruc-
tions. Any maize found to contain over 10 ppb aflatoxin
(the Kenyan regulatory limit for aflatoxin contamination)
is replaced with an equal amount of maize that has been
tested and found to contain less than 10 ppb aflatoxin
(“safe maize”). This component of the intervention has
been in place since July 2013.
The stockist component of the intervention was intro-
duced after trial commencement, in January–February
2014, in response to the observation that many house-
holds were accessing the majority of the maize they con-
sumed through the market. This was unexpected and
arose due to an unusually poor maize harvest in the study
area in 2013. Household maize purchases are typically
small and frequent, so the swapping intervention was
missing a large portion of maize consumed. In the stockist
intervention, Caritas Meru supplies maize containing less
than 10 ppb aflatoxin to at least one shopkeeper in each
of the intervention villages. In geographically larger vil-
lages, safe maize is supplied to multiple shopkeepers to
ensure this maize is accessible to all study participants.
Participating households are encouraged to purchase this
tested maize, which is offered at the lowest price of maize
currently for sale in the village. This encouragement is
through an initial village meeting, as well as the monthly
swapping visits. Participants have been provided with a
laminated ID card displaying their name and unique iden-
tifying number. To ensure that an adequate supply of safe
maize is available to study participants, stockists are asked
to sell maize only to those presenting a study ID card, and
to record all sales in a tracking form which includes a field
for the household unique identifying number.
Participants in villages assigned to the intervention
group were consuming untested, purchased maize for up
to 12 months before the stockist component of the inter-
vention was introduced, half of the study duration of
24 months. Due to the risk that these participants were
exposed to the full intervention for an insufficient length
Hoffmann et al. Trials  (2015) 16:552 Page 3 of 7
of time to have an impact on the primary outcomes of
interest, an additional wave of recruitment was added to
replace this wave of recruits. Wave-1 households in the
intervention group continued to receive the intervention
for a 2-year period, according to the original protocol, but
this group will be excluded from follow-up data collection.
Outcomes and data collection
The primary outcomes are serum aflatoxin B1-lysine ad-
duct level determined using HPLC analysis and linear
growth (assessed using LAZ) of children aged 20–24
months. We focus on the period from before birth to age
24 months because growth faltering occurs primarily dur-
ing this period [17], and the greatest benefits of nutritional
interventions are seen at the youngest ages [18–21]. Data
on household SES, food consumption, and child-feeding
practices are also collected in order to control for these
known determinants of child linear growth and hence re-
duce residual noise and increase power
Data collection at baseline and follow-up occurs at
participants’ homes through face-to-face interviews. A
pre-coded survey was administered to the expectant
mother immediately after enrollment, her height and
weight were measured, and self-reported month of preg-
nancy was recorded. Expectant mothers were also asked
to provide a venous blood sample to be analyzed for
serum aflatoxin. Additional file 3 provides details on the
protocol for blood data collection and analysis of serum
aflatoxin. A similar survey is be repeated during follow-
up data collection at 24 months after enrollment. Partic-
ipants enrolled in the fourth through sixth waves will
additionally be followed-up 24 months after the third
enrollment wave. At each follow-up visit, the length and
weight of the child in utero at baseline (reference child)
will be recorded, and a venous blood sample will be
taken from this child for serum aflatoxin analysis.
Participants will be tracked for follow-up data collec-
tion using global positioning system (GPS) data on the
homestead location and respondent’s phone number col-
lected at enrollment. If the target child has relocated
since enrollment, the child will be followed to the new
home if this is within a sub-location (administrative unit
above the village) included in the study. If the target
child has relocated outside of the study area, or is no
longer living, but the household can be tracked and
contains another child aged between 12 and 24 months,
primary outcome data will be collected for this child.
Data will be collected for all participants tracked during
follow-up data collection, regardless of whether any of
their stored maize was swapped or whether they pur-
chased tested maize from the stockist (Fig. 1).
Data from baseline and follow-up surveys is collected
using handheld tablets on which an electronic data collec-
tion form is programmed. The program includes range
and consistency checks, and automatic skip patterns.
Backcheck surveys consisting of a subset of the survey
questions are administered to randomly selected partici-
pants to ensure data quality. Tablets are sent to the field
office on a regular basis where the data is removed for se-
cure storage.
Study timeline
The first wave of enrollment into the study began in
February 2013, and enrollment of the final wave (wave
6) was completed in November 2014. Follow-up data
collection on wave-2 enrollees began in July 2015. Data
collection for all waves is expected to be completed by
November 2016.
Data analysis plan
Data will be analyzed on an intent-to-treat basis, mean-
ing that non-compliers (participants who refused to
allow their stored maize to be tested and swapped, or
who did not purchase any aflatoxin-safe maize from
stockists) are treated as part of the intervention group
for purposes of analysis. Both unadjusted and adjusted
analysis of covariance (ANCOVA) models will be used
to assess the impact of the intervention, controlling for
mothers’ blood aflatoxin level at enrollment. In all models,
standard errors will be clustered at the village level to
account for within-cluster correlation of outcomes.
Ethics and dissemination
Ethical approval was obtained from the International Food
Policy Research Institute (IFPRI) Institutional Review
Board, and from the African Medical Research Foundation
Ethics and Scientific Review Committee in Kenya, and has
been updated with changes in the protocol after com-
mencement. Approval of changes to protocol modifica-
tions are submitted to the same. Adverse effects, while not
anticipated, would be reported to both of these bodies
immediately.
Identifiers will be used to uniquely identify individuals
and households. Once the data sets have been created,
any information allowing the identification of an individ-
ual or household (such as names and address) will be
stripped from the data sets and destroyed. Any informa-
tion allowing the identification of individuals or house-
holds will be destroyed. Any information obtained in
connection with this study will be used in a manner that
does not publicly disclose any participant’s identity and
will be kept confidential. Only study investigators will
have access to the final data set.
Serum aflatoxin levels at enrollment are reported
back to participants during village-level dissemination
meetings and household visits several months later.
Summary statistics of the baseline blood and maize
aflatoxin results have been reported to the Kenyan
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Ministry of Agriculture, Ministry of Health, and to the
Meru and Tharaka-Nithi County administration offices.
Full results will be provided to the same government
bodies, and submitted for publication in peer-reviewed
journals. Eligibility for authorship will be based on sub-
stantive contribution in three of five of the following
areas: inception, fundraising, data collection, analysis,
and manuscript preparation.
Discussion
This protocol describes the first randomized controlled
trial (RCT) to test for a causal impact of aflatoxin expos-
ure on child growth. Given the strength of this relation-
ship in published observational studies, the hypothesized
health burden associated with an impact on growth, if
present, would almost certainly exceed the known bur-
den due to liver cancer and acute toxicity. Whether or
Fig. 1 Schedule of enrollment, interventions, and assessments. X: discrete point in time during which an event occurs. : continuous
period over which an event occurs
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not such relationship is found, results of the trial will
have implications for the prioritization of aflatoxin con-
trol efforts by governments in affected regions, as well
as international donors, which have been investing heav-
ily in aflatoxin control in recent years [22].
The strength of this study compared to previous work
addressing the same question is its utilization of a ran-
domized controlled design. This approach overcomes
the problem of omitted variable bias: that is, the possi-
bility that the observed relationship between aflatoxin
exposure and impaired child growth is driven by con-
founders. In order to reduce aflatoxin exposure among
those assigned to the control group, the intervention
provides participants with opportunities to have their
stored maize tested and replaced with aflatoxin-safe
maize if contaminated, and to purchase aflatoxin-safe
maize through local stockists. The primary risk to the
study is a lack of demand for these services: if partici-
pants in the treatment group cannot be reached, or do
not submit to having their stored maize tested and
swapped each month, or if they purchase maize from
non-study vendors, aflatoxin exposure may not be suffi-
ciently reduced to impact child growth outcomes. A fur-
ther risk is lack of information on serum aflatoxin
throughout the 2-year study period. Due to budget con-
straints, serum aflatoxin levels are only collected at en-
rollment (from expectant mothers) and from children at
one or two follow-up visits, depending on enrollment
wave. The difference in aflatoxin exposure achieved
through the intervention over the study period as a whole
will be estimated using data on the proportion of stored
maize swapped and the proportion of purchased maize
obtained through study-affiliated stockists. Future trials
using a similar design would ideally collect serum samples
from all children at multiple points in time over the study
period to more precisely estimate exposure.
Trial status
At the time of submission, recruitment had been com-
pleted and the intervention was ongoing. Follow-up data
collection had not yet begun.
Endnotes
1Other affected produce include sorghum, figs and
spices; meat, milk and eggs may contain lower levels of
aflatoxin and its metabolites.
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Additional file 1: SPIRIT 2013 Checklist. A list of recommended items
to address in a clinical trial protocol and related documents, based on
the 2013 SPIRIT (Standard Protocol Items: Recommendations for
Interventional Trials) guidelines. (DOC 120 kb)
Additional file 2: Consent form. A description of study aims, procedures,
risks, and benefits read to prospective participants during the informed
consent process. (DOCX 65 kb)
Additional file 3: Protocol for blood data collection and analysis of
serum aflatoxin. Protocol for blood data collection from study subjects
and subsequent analysis of serum for aflatoxin. (DOCX 18 kb)
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